vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and ON24 INC. (ONTF). Click either name above to swap in a different company.
ON24 INC. is the larger business by last-quarter revenue ($34.6M vs $18.7M, roughly 1.9× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -18.8%, a 17.9% gap on every dollar of revenue. On growth, ON24 INC. posted the faster year-over-year revenue change (-5.6% vs -25.7%). ON24 INC. produced more free cash flow last quarter ($-2.2M vs $-15.8M). Over the past eight quarters, ON24 INC.'s revenue compounded faster (-4.2% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
ON24 Inc., a San Francisco-based company, is a cloud-based platform that develops and sells web-based webinar, virtual conferencing, content hub, and landing page applications as a service for marketing and sales teams in B2B organizations. In 2023 it expanded its offerings to include generative AI services.
CTMX vs ONTF — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $34.6M |
| Net Profit | $-154.0K | $-6.5M |
| Gross Margin | — | 74.9% |
| Operating Margin | -6.9% | -23.5% |
| Net Margin | -0.8% | -18.8% |
| Revenue YoY | -25.7% | -5.6% |
| Net Profit YoY | 97.6% | 26.8% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $34.6M | ||
| Q3 25 | — | $34.6M | ||
| Q2 25 | $18.7M | $35.3M | ||
| Q1 25 | $50.9M | $34.7M | ||
| Q4 24 | $38.1M | $36.7M | ||
| Q3 24 | $33.4M | $36.3M | ||
| Q2 24 | $25.1M | $37.3M | ||
| Q1 24 | $41.5M | $37.7M |
| Q4 25 | — | $-6.5M | ||
| Q3 25 | — | $-6.4M | ||
| Q2 25 | $-154.0K | $-7.3M | ||
| Q1 25 | $23.5M | $-8.7M | ||
| Q4 24 | $18.9M | $-8.9M | ||
| Q3 24 | $5.7M | $-11.4M | ||
| Q2 24 | $-6.5M | $-11.2M | ||
| Q1 24 | $13.8M | $-10.7M |
| Q4 25 | — | 74.9% | ||
| Q3 25 | — | 74.7% | ||
| Q2 25 | — | 75.1% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | 74.5% | ||
| Q3 24 | — | 74.3% | ||
| Q2 24 | — | 74.5% | ||
| Q1 24 | — | 74.1% |
| Q4 25 | — | -23.5% | ||
| Q3 25 | — | -23.1% | ||
| Q2 25 | -6.9% | -26.0% | ||
| Q1 25 | 44.4% | -30.1% | ||
| Q4 24 | 46.4% | -32.1% | ||
| Q3 24 | 12.3% | -36.7% | ||
| Q2 24 | -33.7% | -35.0% | ||
| Q1 24 | 28.1% | -33.1% |
| Q4 25 | — | -18.8% | ||
| Q3 25 | — | -18.4% | ||
| Q2 25 | -0.8% | -20.6% | ||
| Q1 25 | 46.2% | -25.1% | ||
| Q4 24 | 49.6% | -24.2% | ||
| Q3 24 | 17.2% | -31.4% | ||
| Q2 24 | -26.0% | -29.9% | ||
| Q1 24 | 33.3% | -28.4% |
| Q4 25 | — | $-0.15 | ||
| Q3 25 | — | $-0.15 | ||
| Q2 25 | — | $-0.17 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.21 | ||
| Q3 24 | — | $-0.27 | ||
| Q2 24 | — | $-0.27 | ||
| Q1 24 | — | $-0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $37.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $139.4M |
| Total Assets | $175.1M | $228.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $37.0M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | $49.0M | $37.7M | ||
| Q1 25 | $47.6M | $26.8M | ||
| Q4 24 | $38.1M | $14.9M | ||
| Q3 24 | $40.6M | $11.0M | ||
| Q2 24 | $43.2M | $15.5M | ||
| Q1 24 | $36.2M | $18.3M |
| Q4 25 | — | $139.4M | ||
| Q3 25 | — | $144.3M | ||
| Q2 25 | $119.9M | $150.0M | ||
| Q1 25 | $25.0M | $153.7M | ||
| Q4 24 | $-456.0K | $159.4M | ||
| Q3 24 | $-23.5M | $164.9M | ||
| Q2 24 | $-31.2M | $170.8M | ||
| Q1 24 | $-31.7M | $174.4M |
| Q4 25 | — | $228.4M | ||
| Q3 25 | — | $224.8M | ||
| Q2 25 | $175.1M | $235.1M | ||
| Q1 25 | $98.5M | $245.8M | ||
| Q4 24 | $120.5M | $251.0M | ||
| Q3 24 | $139.0M | $250.9M | ||
| Q2 24 | $159.2M | $259.0M | ||
| Q1 24 | $184.7M | $269.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-1.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $-2.2M |
| FCF MarginFCF / Revenue | -84.6% | -6.4% |
| Capex IntensityCapex / Revenue | 0.1% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $4.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | $-15.8M | $2.6M | ||
| Q1 25 | $-21.0M | $3.4M | ||
| Q4 24 | $-19.9M | $985.0K | ||
| Q3 24 | $-20.7M | $295.0K | ||
| Q2 24 | $-19.5M | $1.4M | ||
| Q1 24 | $-26.0M | $2.1M |
| Q4 25 | — | $-2.2M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $-15.8M | $2.1M | ||
| Q1 25 | $-21.2M | $1.9M | ||
| Q4 24 | $-20.0M | $424.0K | ||
| Q3 24 | $-20.7M | $143.0K | ||
| Q2 24 | $-19.6M | $898.0K | ||
| Q1 24 | $-26.2M | $1.1M |
| Q4 25 | — | -6.4% | ||
| Q3 25 | — | 6.2% | ||
| Q2 25 | -84.6% | 5.9% | ||
| Q1 25 | -41.6% | 5.6% | ||
| Q4 24 | -52.5% | 1.2% | ||
| Q3 24 | -62.1% | 0.4% | ||
| Q2 24 | -78.2% | 2.4% | ||
| Q1 24 | -63.1% | 2.9% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | 0.1% | 1.4% | ||
| Q1 25 | 0.2% | 4.2% | ||
| Q4 24 | 0.2% | 1.5% | ||
| Q3 24 | 0.1% | 0.4% | ||
| Q2 24 | 0.4% | 1.3% | ||
| Q1 24 | 0.3% | 2.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
ONTF
Segment breakdown not available.
